Results
Ten patients at six CF centers with a median age of 22.1 years (range
14-43.4 years) and median time from transplant of 6.9 years (range
0.6-22 years) were included. Most patients (8, 80%) received a reduced
or full dose of elx/tez/iva for a mean duration of 10.4 months (range
7-12 months). Fluctuations in LFTs occurred in all patients (10, 100%)
and led to therapy discontinuation in two patients (20%). Elx/tez/iva
initiation resulted in elevations in tacrolimus trough concentration in
7 patients (70%). Most patients who tolerated elx/tez/iva had
symptomatic and quality of life improvement, increased body-mass-index,
and maintained or improved lung function.